2型糖尿病合并动脉粥样硬化性心血管疾病患者降糖药物应用专家共识

2017-06-30 中国内分泌相关专家小组(统称) 中国糖尿病杂志.2017,25(6):481-492.

动脉粥样硬化性心血管疾病(ASCVD) 包括冠心病、缺血性卒中及外周动脉疾病, 是2型糖尿病(T2DM) 患者致死和致残的主要原因。目前国内外糖尿病防治指南均推荐, 对于T2DM患者, 必须加强髙血糖、高血压、血脂异常、肥胖等多重心血管危险因素的综合管理, 以最大限度降低心血管事件和死亡风险。近年来, 由于美国FDA的强制性要求, 全球已完成或正在开展一系列新型降糖药物的心血管结局研究(CVOT)

中文标题:

2型糖尿病合并动脉粥样硬化性心血管疾病患者降糖药物应用专家共识

发布日期:

2017-06-30

简要介绍:

动脉粥样硬化性心血管疾病(ASCVD) 包括冠心病、缺血性卒中及外周动脉疾病, 是2型糖尿病(T2DM) 患者致死和致残的主要原因。目前国内外糖尿病防治指南均推荐, 对于T2DM患者, 必须加强髙血糖、高血压、血脂异常、肥胖等多重心血管危险因素的综合管理, 以最大限度降低心血管事件和死亡风险。近年来, 由于美国FDA的强制性要求, 全球已完成或正在开展一系列新型降糖药物的心血管结局研究(CVOT)。已经公布的两项CVOT显示, 在伴有心血管疾病或高危因素的T2DM患者中, 恩格列净和利拉鲁肽可显著降低心血管事件和死亡风险。因此, 本共识建议,对于T2DM合并ASCVD患者,在选择降糖药物时, 除关注降糖疗效外, 还应特别注意心血管安全性问题; 对于血糖控制不佳的这类患者,在二甲双胍等标准治疗的基础上可考虑优先选择具有明确心血管获益证据的降糖药物(如利拉鲁肽或恩格列净)治疗。



拓展指南:糖尿病相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=2型糖尿病合并动脉粥样硬化性心血管疾病患者降糖药物应用专家共识)] GetToolGuiderByIdResponse(projectId=1, id=07fcf1c001a668d7, title=2型糖尿病合并动脉粥样硬化性心血管疾病患者降糖药物应用专家共识, enTitle=, guiderFrom=中国糖尿病杂志.2017,25(6):481-492., authorId=null, author=, summary=动脉粥样硬化性心血管疾病(ASCVD) 包括冠心病、缺血性卒中及外周动脉疾病, 是2型糖尿病(T2DM) 患者致死和致残的主要原因。目前国内外糖尿病防治指南均推荐, 对于T2DM患者, 必须加强髙血糖、高血压、血脂异常、肥胖等多重心血管危险因素的综合管理, 以最大限度降低心血管事件和死亡风险。近年来, 由于美国FDA的强制性要求, 全球已完成或正在开展一系列新型降糖药物的心血管结局研究(CVOT), cover=, journalId=null, articlesId=null, associationId=666, associationName=中国内分泌相关专家小组(统称), associationIntro=这是一个统称,其下指南和专家共识均由国内内分泌领域的专家制定。, copyright=0, guiderPublishedTime=Fri Jun 30 00:00:00 CST 2017, originalUrl=, linkOutUrl=, content=动脉粥样硬化性心血管疾病(ASCVD) 包括冠心病、缺血性卒中及外周动脉疾病, 是2型糖尿病(T2DM) 患者致死和致残的主要原因。目前国内外糖尿病防治指南均推荐, 对于T2DM患者, 必须加强髙血糖、高血压、血脂异常、肥胖等多重心血管危险因素的综合管理, 以最大限度降低心血管事件和死亡风险。近年来, 由于美国FDA的强制性要求, 全球已完成或正在开展一系列新型降糖药物的心血管结局研究(CVOT)。已经公布的两项CVOT显示, 在伴有心血管疾病或高危因素的T2DM患者中, 恩格列净和利拉鲁肽可显著降低心血管事件和死亡风险。因此, 本共识建议,对于T2DM合并ASCVD患者,在选择降糖药物时, 除关注降糖疗效外, 还应特别注意心血管安全性问题; 对于血糖控制不佳的这类患者,在二甲双胍等标准治疗的基础上可考虑优先选择具有明确心血管获益证据的降糖药物(如利拉鲁肽或恩格列净)治疗。 <div><br> </div> <div><br> </div> 拓展指南:<strong>与<font color=red>糖尿病</font>相关指南:</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=6e3741c001a65561" title="2017 ACOG实践简报:妊娠期糖尿病(No.180)" target=_blank>2017 ACOG实践简报:妊娠期糖尿病(No.180)</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=adce11c001a538ff" title="非酒精性脂肪性肝病的治疗—欧洲肥胖-2型糖尿病-消化临床实践指南解读" target=_blank>非酒精性脂肪性肝病的治疗—欧洲肥胖-2型糖尿病-消化临床实践指南解读</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=289d41c001a46542" title="2017 亚洲国家循证治疗建议:糖尿病性黄斑水肿" target=_blank>2017 亚洲国家循证治疗建议:糖尿病性黄斑水肿</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=094761c001a44164" title="糖尿病微循环障碍临床用药专家共识" target=_blank>糖尿病微循环障碍临床用药专家共识</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=d797f1c001a4334e" title="【精品】2016 SOGC临床实践指南:妊娠糖尿病(英文版、中文版及要点解读)" target=_blank>【精品】2016 SOGC临床实践指南:妊娠糖尿病(英文版、中文版及要点解读)</a></li> 更多信息请点击:<a href="http://www.medsci.cn/guideline/list.do?q=%E7%B3%96%E5%B0%BF%E7%97%85" target=_blank>有关糖尿病更多指南</a></ul>, tagList=[TagDto(tagId=2052, tagName=2型糖尿病), TagDto(tagId=828, tagName=动脉粥样硬化), TagDto(tagId=2529, tagName=心血管疾病)], categoryList=[CategoryDto(categoryId=6, categoryName=内分泌科, tenant=100), CategoryDto(categoryId=8, categoryName=糖尿病, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=7608, appHits=510, showAppHits=0, pcHits=4772, showPcHits=3166, likes=152, shares=39, comments=4, approvalStatus=1, publishedTime=Tue Jul 11 22:22:42 CST 2017, publishedTimeString=2017-06-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Tue Jul 11 22:22:42 CST 2017, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 16:13:11 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2型糖尿病合并动脉粥样硬化性心血管疾病患者降糖药物应用专家共识)])
2型糖尿病合并动脉粥样硬化性心血管疾病患者降糖药物应用专家共识
下载请点击:
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=236311, encodeId=2b1823631143, content=不错.有指导性, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56012097942, createdName=清风清茶, createdTime=Wed Aug 23 09:23:37 CST 2017, time=2017-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=224435, encodeId=c09222443517, content=学习了,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Fri Jul 21 00:20:03 CST 2017, time=2017-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222758, encodeId=15e6222e586e, content=学习了,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Sun Jul 16 07:02:12 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222249, encodeId=ab8822224978, content=给我们心内科的上了一堂很好的内分泌知识宣教, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95cd2071972, createdName=1351f04fe4m, createdTime=Fri Jul 14 15:20:24 CST 2017, time=2017-07-14, status=1, ipAttribution=)]
    2017-08-23 清风清茶

    不错.有指导性

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=236311, encodeId=2b1823631143, content=不错.有指导性, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56012097942, createdName=清风清茶, createdTime=Wed Aug 23 09:23:37 CST 2017, time=2017-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=224435, encodeId=c09222443517, content=学习了,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Fri Jul 21 00:20:03 CST 2017, time=2017-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222758, encodeId=15e6222e586e, content=学习了,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Sun Jul 16 07:02:12 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222249, encodeId=ab8822224978, content=给我们心内科的上了一堂很好的内分泌知识宣教, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95cd2071972, createdName=1351f04fe4m, createdTime=Fri Jul 14 15:20:24 CST 2017, time=2017-07-14, status=1, ipAttribution=)]
    2017-07-21 惠映实验室

    学习了,谢谢

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=236311, encodeId=2b1823631143, content=不错.有指导性, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56012097942, createdName=清风清茶, createdTime=Wed Aug 23 09:23:37 CST 2017, time=2017-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=224435, encodeId=c09222443517, content=学习了,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Fri Jul 21 00:20:03 CST 2017, time=2017-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222758, encodeId=15e6222e586e, content=学习了,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Sun Jul 16 07:02:12 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222249, encodeId=ab8822224978, content=给我们心内科的上了一堂很好的内分泌知识宣教, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95cd2071972, createdName=1351f04fe4m, createdTime=Fri Jul 14 15:20:24 CST 2017, time=2017-07-14, status=1, ipAttribution=)]
    2017-07-16 惠映实验室

    学习了,谢谢

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=236311, encodeId=2b1823631143, content=不错.有指导性, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56012097942, createdName=清风清茶, createdTime=Wed Aug 23 09:23:37 CST 2017, time=2017-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=224435, encodeId=c09222443517, content=学习了,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Fri Jul 21 00:20:03 CST 2017, time=2017-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222758, encodeId=15e6222e586e, content=学习了,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Sun Jul 16 07:02:12 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222249, encodeId=ab8822224978, content=给我们心内科的上了一堂很好的内分泌知识宣教, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95cd2071972, createdName=1351f04fe4m, createdTime=Fri Jul 14 15:20:24 CST 2017, time=2017-07-14, status=1, ipAttribution=)]
    2017-07-14 1351f04fe4m

    给我们心内科的上了一堂很好的内分泌知识宣教

    0